Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Docetaxel

FDA-approved product (injectable, injection), marketed as Beizray, Docefrez, Docetaxel and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Docetaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Gastric adenocarcinoma
  • Gastric cancer
  • Gastric carcinoma
  • Gastroesophageal junction adenocarcinoma
  • Head and neck carcinoma
  • Head and neck malignant neoplasia
  • Head and neck neoplasia
  • Head and neck squamous cell carcinoma
  • Malignant tumor of neck
  • Metastatic prostate cancer
  • Neoplasm
  • and 6 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
FDA pharmacologic class
Microtubule Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Docetaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Docetaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer

    NCT00256360 · start 2005-09

    Registered record
    Registry ID
    NCT00256360
    Conditions
    Breast Cancer
    Interventions
    dose dense with neulasta
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    2006-05
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiondose dense with neulasta
    PhasePhase 2
    Registry statusCompleted

  • Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer

    NCT00258362 · start 2005-07

    Registered record
    Registry ID
    NCT00258362
    Conditions
    Endometrial Cancer
    Interventions
    carboplatin; docetaxel; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-07
    Completion
    2009-12
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Cancer
    Interventioncarboplatin; docetaxel; radiation therapy
    PhasePhase 2
    Registry statusCompleted

  • Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

    NCT00217672 · start 2005-05

    Registered record
    Registry ID
    NCT00217672
    Conditions
    Breast Cancer
    Interventions
    bevacizumab; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-05
    Completion
    2010-11
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionbevacizumab; Docetaxel
    PhasePhase 2
    Registry statusCompleted

  • Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract

    NCT03159143 · start 2004-12-17

    Registered record
    Registry ID
    NCT03159143
    Conditions
    Metastatic Transitional Cell Cancer of the Urothelial Tract
    Interventions
    Docetaxel; Oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-12-17
    Completion
    2009-12-02
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Transitional Cell Cancer of the Urothelial Tract
    InterventionDocetaxel; Oxaliplatin
    PhasePhase 2
    Registry statusCompleted

  • Taxotere + Cisplatin in Nasopharyngeal Carcinoma

    NCT00436293 · start 2002-12

    Registered record
    Registry ID
    NCT00436293
    Conditions
    Nasopharyngeal Neoplasms
    Interventions
    Docetaxel; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-12
    Completion
    2010-03
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasopharyngeal Neoplasms
    InterventionDocetaxel; Cisplatin
    PhasePhase 2
    Registry statusCompleted